Sorafenib is used worldwide as a first-line standard systemic agent for advanced hepatocellular carcinoma(HCC)on the basis of the results of two large-scale Pha
Drugs fulfilling the criterion of a standard drug will always become panacea provided,if they are used properly.On the other hand,a poorly manufactured drug how